The prizewinners, from left to right: - Achim Göpferich (University of Regensburg), Thomas Kurz (Heinrich Heine University Düsseldorf), Jens Schlossmann (University of Regensburg) and Evi Kostenis (University of Bonn).
The prizewinners, from left to right: - Achim Göpferich (University of Regensburg), Thomas Kurz (Heinrich Heine University Düsseldorf), Jens Schlossmann (University of Regensburg) and Evi Kostenis (University of Bonn). Photo montage: PHoeNIX group all images in original size . Carvedilol is a beta blocker that is often prescribed to lower blood pressure or prevent heart attacks. Professor Evi Kostenis from the Institute of Pharmaceutical Biology at the University of Bonn has contributed to a better understanding of how this drug works as the corresponding author for an article published in the journal "Nature Communications." Kostenis's research team has been presented with a ¤10,000 PHoeNIX Pharmaceutical Science Prize in recognition of this important discovery. For some years now, beta blockers have been a key tool in the treatment of congestive heart failure in patients recovering from a heart attack. They influence beta receptors in the sympathetic nervous system and thus reduce the heart's excitability. Carvedilol is one such beta blocker that is regarded as being particularly good at prolonging the long-term survival of patients with heart failure.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
Your Benefits
- Access to all content
- Receive newsmails for news and jobs
- Post ads
